Wire · operational-macro
PDS Biotech secures USD 11.3m initial PIPE to fund PDS0301 Phase III protocol submission
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
PDS Biotechnology secured an initial USD 11.3 million PIPE financing to support submission of the Phase III clinical trial protocol for PDS0301, a tumor-targeted immunocytokine, to the FDA with a contingent USD 11 million closing linked to the trial submission. The financing enables advancement of late-stage development and includes strategic board appointments from Nant Capital.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a new channel for funding late-stage immuno-oncology trials as PIPEs tied to regulatory milestones gain traction, especially with influential partners joining your board. Shifting from internal to partnered development for PDS0101 signals external collaboration is now a practical path to market.
◆ Coverage
1 source · 15 Sep 2026
◆ Related on Wire
◆ Topics